Beacon produces antiviral drug Favipiravir to fight Covid-19

Beacon Pharmaceuticals Limited has developed an antiviral drug Favipiravir, better known as Avigan, accelerating treatment for the people infected with the novel coronavirus (Covid-19).

In 2014, Fujifilm Toyama Chemical Company invented the drug first in Japan and the drug was used in treating the people who were infected with Ebola virus, said a press release of the number one oncology drug manufacturer company in Bangladesh.

Chinese medical authorities in Wuhan and Shenzhen provinces have started using the drug for treating the people infected with the Covid-19, on trial basis, for its broad spectrum of antiviral effectiveness.

The antiviral Favipiravir drug helps reducing treatment time and increasing efficiency of lungs of the Covid-19 patients. A clinical report shows that the drug has already been used on around 340 patients.

On March 28 this year, Japanese Prime Minister Shinzo Abe said that a process to add the medicine with the standard treatment system in the country will begin immediately.

A few more countries have already claimed to have found positive results during its experimental use, he said.

The drug has already created a light of hope for the Covid-19 patients.

Md Ebadul Karim MP, who is also managing director of Beacon, a leading pharmaceutical company, said his company has already produced the first batch of the medicine and handed it over to the director general of the Directorate General of Drug Administration, seeking approval for its trial, according to press release.